TVRD

Tvardi Therapeutics, Inc. TVRD

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,906 of 2,925

Why it scores 7Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Top Institutional Holders

as of Q2 2026
$4.24M total
Slate Path Capital LP
$1.34M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$654.3K-0.1%
AMERICAN FINANCIAL GROUP INC
$425.0K0.0%
UBS Group AG
$211.2K+120.3%
SILVERCREST ASSET MANAGEMENT GROUP LLC
$192.0K0.0%
BlackRock, Inc.
$181.4K-75.4%
RENAISSANCE TECHNOLOGIES LLC
$173.7K-0.8%
GEODE CAPITAL MANAGEMENT, LLC
$171.7K-50.4%
MORGAN STANLEY
$147.9K+6.8%
Duncan Williams Asset Management, LLC
$120.2K0.0%
VANGUARD FIDUCIARY TRUST CO
$84.9K-4.6%
Russell Investments Group, Ltd.
$82.1K+85.5%
STATE STREET CORP
$64.4K-65.1%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$63.0KNew
AQR CAPITAL MANAGEMENT LLC
$51.5K-35.8%
Savant Capital, LLC
$49.4KNew
NORTHERN TRUST CORP
$41.5K-55.5%
GSA CAPITAL PARTNERS LLP
$34.0KNew
DIADEMA PARTNERS LP
$31.6KNew
XTX Topco Ltd
$28.2KNew
BROWN ADVISORY INC
$21.3KNew
SRS Capital Advisors, Inc.
$20.9K+32.0%
Qube Research & Technologies Ltd
$19.4KNew
Persistent Asset Partners Ltd
$8.1KNew
PNC FINANCIAL SERVICES GROUP, INC.
$6.7K+577.8%
See all 58 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/TVRD

Earnings Per Share

13fpro.ai/company/TVRD

Loading ratio trend…

TVRD key financials by period

Reported revenue, net income and operating margin by fiscal year, from Tvardi Therapeutics, Inc.'s annual filings on SEC EDGAR.

Tvardi Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$7.1M$-29.4M—
FY 2023$21.0M$-118.5M—
FY 2022$41.9M$-85.5M—
FY 2021$23.0M$-88.4M—
FY 2020$135.1M$8.4M4.0%
FY 2019$19.9M$-106.4M—
Source: TVRD filings on SEC EDGAR →

TVRD insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Tvardi Therapeutics, Inc. (TVRD): stock profile, AI score and financials

Tvardi Therapeutics, Inc. (TVRD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TVRD at 7.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,906 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TVRD by reported 13-F value include Slate Path Capital, VANGUARD CAPITAL MANAGEMENT, AMERICAN FINANCIAL GROUP, based on the most recent SEC filings. TVRD trades on the Nasdaq exchange and files with the SEC under CIK 1346830. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVRD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tvardi Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1346830 →